Avtor/Urednik		Čufer, Tanja; Ovčariček, Tanja; O'Brien, Mary E. R.
Naslov		Systemic therapy of advanced non-small cell lung cancer
Tip		članek
Vol. in št.		Letnik 49, št. 6
Leto izdaje		2013
Obseg		str. 1216-1225
ISSN		0959-8049 - European journal of cancer (Oxford, England : 1990)
Jezik		eng
Abstrakt		The standard palliative treatment for advanced stage NSCLC remains a platinum doublet but by tailoring chemotherapy according to tumour histology the results can be improved through using pemetrexed-containing schemas in non-squamous-cell disease. In addition, maintenance chemotherapy appears to be effective in patients achieving clinical benefit by induction therapy. Targeted therapy based on the presence of activating epidermal growth factor receptor (EGFR) activating mutations or EML4-ALK gene rearrangement is becoming standard practice with high median survival rates, up to 30 months. There are still numerous other molecular targeted drugs in development. This review presents the most recent relevant progress in systemic anti-cancer therapy of advanced NSCLC in the past 5 years and delineates today's new treatment options.
Proste vsebinske oznake		non-small cell lung cancer advanced disease new systemic therapies